NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company specializing in nanomaterials for antiviral therapy, announced it has entered into a securities purchase agreement with a single fundamental institutional investor to raise approximately $3.8 million in gross proceeds through a registered direct offering. The transaction involves the sale of 2,516,339 common shares or pre-funded warrants, along with warrants to purchase an equal number of common shares. Each full warrant carries an exercise price of $1.75 per share and expires five and a half years after issuance. D. Boral Capital LLC is serving as the exclusive placement agent. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions.
This capital infusion comes at a critical time for NanoViricides as it focuses on advancing its lead drug candidate, NV-387, into Phase II human clinical trials. NV-387 is a broad-spectrum antiviral drug designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company also has NV-HHV-1, a candidate for treating shingles, in its pipeline. The proceeds from this offering will likely support the company's efforts to move these drug candidates through the development pipeline, which is capital-intensive and fraught with regulatory hurdles.
The importance of this funding cannot be overstated for NanoViricides and the broader antiviral therapeutics landscape. The company's nanoviricide technology, based on intellectual property and proprietary know-how licensed from TheraCour Pharma, Inc., represents a novel approach to antiviral therapy. Unlike traditional small-molecule drugs, nanoviricides are designed to specifically target and dismantle viruses, potentially offering broad-spectrum activity. If successful, NV-387 could address significant unmet medical needs, particularly for viruses like RSV and influenza, for which current treatments are limited. Additionally, the company has developed two drug candidates for COVID-19: NV-CoV-2, which does not encapsulate remdesivir, and NV-CoV-2-R, which encapsulates remdesivir within its polymeric micelles. NanoViricides believes that NV-CoV-2-R could be an approvable drug given remdesivir's existing FDA approval, provided safety profiles are comparable.
For investors, this offering signals continued institutional confidence in NanoViricides' technology and clinical prospects. However, the company acknowledges the inherent risks in drug development, noting that the path to commercialization is extremely lengthy and requires substantial capital. There is no assurance that any of its candidates will demonstrate sufficient effectiveness and safety for human clinical development or lead to a successful product. The company's business model relies on licensing technology from TheraCour Pharma for specific virus applications, and it holds exclusive perpetual licenses for several human viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes, influenza, dengue, and certain coronaviruses.
The broader implications for the antiviral drug market are significant. If NanoViricides' nanoviricide platform proves effective, it could revolutionize the treatment of viral infections by providing a single therapeutic approach for multiple viruses. This would reduce the need for virus-specific drug development and potentially lower healthcare costs. However, the company remains in early clinical stages, and the success of NV-387 in Phase II trials will be a critical milestone. For more information, visit the company's newsroom at https://nnw.fm/NNVC and the full press release at https://nnw.fm/2qH5W.
